Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 24, 2026

3 Monster Dividend Stocks to Hold for the Next 10 Years

View original at nasdaq.com
3 Monster Dividend Stocks to Hold for the Next 10 Years Key Points AbbVie is a Dividend King that has demonstrated its ability to adapt effectively to daunting challenges…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AbbVie's pipeline includes around 90 programs, of which roughly 60 are in mid- or late-stage clinical trials

    60% confidence
  • Stock Advisor's total average return is 986%, a market-crushing outperformance compared to 208% for the S&P 500

    60% confidence
  • Enterprise Products Partners pays a distribution yield of 5.5% and has increased its distribution for 27 consecutive years

    60% confidence
  • Virginia is the home to the world's largest data center market

    60% confidence
  • NextEra expects the dividend to rise by roughly 10% in 2026, followed by an average annual growth rate of approximately 6% through 2028

    60% confidence
  • NextEra Energy ranks as the largest utility company by market cap

    60% confidence
  • If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes.

    60% confidence
  • AbbVie is a member of the Dividend Kings with a 53-year streak of consecutive dividend increases, including time as part of Abbott Labs, and a forward dividend yield topping 3.2%

    60% confidence
  • Enterprise Products Partners generated resilient cash flow throughout major energy sector disruptions including the 2007-2009 financial crisis, the 2015-2017 oil price collapse, and the 2020-2022 COVID-19 pandemic

    60% confidence
  • AbbVie's growth barely skipped a beat after Humira lost patent exclusivity, thanks to investments in R&D and smart acquisitions that added new growth drivers

    60% confidence
  • NextEra targets compound annual growth in adjusted earnings per share of at least 8% through 2035

    60% confidence
  • Data centers hosting AI applications require massive amounts of electric power; natural gas is a great fit for fueling power plants serving these data centers, which should translate to higher volumes through Enterprise's pipelines

    60% confidence
  • NextEra Energy is also the world leader in renewable energy and battery storage

    60% confidence

Data points we hold from this source

AbbVie Inc. · mid late stage clinical trials60 programs
AbbVie Inc. · consecutive dividend increases53 years
AbbVie Inc. · pipeline total programs90 programs
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
3 Monster Dividend Stocks to Hold for the Next 10 Years — Source | Via News | Via News